Clinical trial • Phase I • Oncology
Clinical trial in Malignant pleural mesothelioma | Epithelioid malignant pleural mesothelioma
Phase I trial for Malignant pleural mesothelioma | Epithelioid malignant pleural mesothelioma. 14 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Malignant pleural mesothelioma | Epithelioid malignant pleural mesothelioma
- Trial Stage
- Phase I
- Drug Modality
- Cell therapy
Key dates
- Initial CTIS Submission Date
- 29-07-2024
- First CTIS Authorization Date
- 12-08-2024
Trial design
Phase I trial across 1 site in Netherlands.
- Target Sample Size
- 14
Recruitment
- Planned Sample Size
- 14
- Recruitment Window Months
- 48
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 14
Netherlands
- Earliest CTIS Part Ii Submission Date
- 08-08-2024
- Latest Decision Or Authorization Date
- 12-08-2024
- Processing Time Days
- 4
- Number Of Sites
- 1
- Number Of Participants
- 14
Sites
- Site Name
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
- Department Name
- Pulmonary Science
- Principal Investigator Name
- Joachim G.J.V. Aerts
- Principal Investigator Email
- j.aerts@erasmusmc.nl
- Contact Person Name
- Joachim G.J.V. Aerts
- Contact Person Email
- j.aerts@erasmusmc.nl
- Number Of Participants
- 14
Sponsor
Primary sponsor
- Full Name
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Netherlands
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)